Yazar "Cil, T." seçeneğine göre listele
Listeleniyor 1 - 19 / 19
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Concurrent chemoradiotherapy with or without low molecular weigth heparin (LWMH) in the treatment of locally avanced non-small cell lung cancer (NSCLC)(Amer Soc Clinical Oncology, 2010) Isikdogan, A.; Kaplan, M. A.; Zincircioglu, S. B.; Cit, M.; Cil, T.; Karadayi, B.; Dirier, A.[Abstract Not Available]Öğe Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme(Zerbinis Medical Publ, 2012) Zincircioglu, S. B.; Kaplan, M. A.; Isikdogan, A.; Cil, T.; Karadayi, B.; Dirier, A.; Kucukoner, M.Purpose: Glioblastoma multiforme (GBM) is the most common brain tumor in adults and has a very aggressive course. Median survival is as short as 2 years with standard treatment (chemoradiotherapy followed by adjuvant temozolomide). The purpose of this study was to determine the contribution of low molecular weight heparin (LMWH) addition to concomitant chemoradiotherapy in the treatment of GBM. Methods: All patients with newly diagnosed GBM between March 2004-May 2009 were evaluated. After surgical intervention (total, subtotal resection or only biopsy) all of them were treated with concomitant chemoradiotherapy (2 Gy daily, 5 days a week, 30 fractions, total tumor dose 60 Gy; and 75 mg/m(2) temozolomide, 7 days a week), followed by adjuvant temozolomide (6 cycles, 150-200 mg/m(2), 5 days every 28 days), with or without LMWH (4000 IU/day, 7 days a week, concomitant with radiotherapy) because of risk of thrombosis. The primary endpoint was the determination of progression-free survival (PFS) and overall survival (OS); secondary endpoints were 1- and 2-year OS survival. Results: 30 patients (13 patients in the group non receiving LMWH (LMWH-) and 17 patients in the group receiving LMWH (LMWH+)) were included in the study Median age was 54 years (range 24-75). Median PFS was 57 and 38 weeks in LMWH+ and LMWH- groups, respectively (p=0.068). Median OS was 69 and 44 weeks (p=0.095), 1-year OS survival 84.6 and 41.2% (p=0.016), and 2-year OS survival 38.5 and 5.9% in LMWH+ and LMWH-, respectively (p=0.061). No significant difference was noted between the two groups for grade 3-4 toxicity (p>0.05). Conclusion: Better PFS, OS and 2-year OS survival were obtained in present study with the addition of LMWH to concomitant chemoradiation for GBM but without statistical significance. One-year OS survival was statistically significant favoring the LMWH group. The addition of LMWH did not increase temozolomide toxicityÖğe CONTRIBUTION OF LOW-MOLECULAR WEIGHT HEPARIN ADDITION TO CONCOMITANT CHEMORADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOME MULTIFORME(Oxford Univ Press, 2010) Zincircioglu, S. B.; Kaplan, M. A.; Isikdogan, A.; Cil, T.; Kucukoner, M.; Karadayi, B.; Dirier, A.[Abstract Not Available]Öğe The corelation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma(Amer Soc Clinical Oncology, 2008) Bestas, R.; Isikdogan, A.; Cil, T.; Batun, S.; Altintas, A.[Abstract Not Available]Öğe Efficacy of recombinant FVIIA treatment in inhibitor positive hemophilic patients and in Glanzmann thrombasthenia: Single center experience(Ferrata Storti Foundation, 2007) Altintas, A.; Pasa, S.; Urakci, Z.; Muftuoglu, O. E.; Cil, T.[Abstract Not Available]Öğe THE EFFICACY OF RITUXIMAB IN PATIENTS WITH SPLENECTOMIZED REFRACTORY CHRONIC IDIOPATHIC THROMBOCYTHOPENIC PURPURA(Ferrata Storti Foundation, 2008) Pasa, S.; Altintas, A.; Cil, T.; Danis, R.; Ayyildiz, O.[Abstract Not Available]Öğe Factor V leiden and G20210A prothrombin mutations in patient with recurrent pregnancy loss: Data from southeast of Turkey(Ferrata Storti Foundation, 2007) Altintas, A.; Pasa, S.; Ayyildiz, O.; Cil, T.[Abstract Not Available]Öğe Hepatitis B and C viruses seroprevalence of cancer patients in southeastern region of Turkey(Pergamon-Elsevier Science Ltd, 2007) Cil, T.; Altintas, A.; Pasa, S.; Kaplan, M.; Isikdogan, A.[Abstract Not Available]Öğe Hereditary hemochromatosis gene mutations in the south eastern region of Turkey(Ferrata Storti Foundation, 2007) Altintas, A.; Pasa, S.; Cil, T.; Devecioglu, B.; Ayyildiz, O.[Abstract Not Available]Öğe How to Increase the Diagnostic Value of Malignancy-related Ascites: Discriminative Ability of the Ascitic Tumour Markers(Field House Publishing Llp, 2009) Tuzun, Y.; Yilmaz, M.; Dursun, M.; Canoruc, F.; Celik, Y.; Cil, T.; Boyraz, T.Making a differential diagnosis between malignant and non-malignant ascites is an important clinical issue, but cytological examination has a relatively low diagnostic sensitivity. This study aimed to find a discriminative model that distinguished between malignancy-related and non-malignant ascites. The study included 107 patients: 50 with nonmalignant and 57 with malignant ascites. Ascites was analysed using a range of tumour markers and standard cytology. Standardized canonical discriminant function coefficients were used to distinguish between ascites types. The combination of carbohydrate antigen (CA) 15-3, carcinoembryonic antigen (CEA) and cytokeratin 19 fragments (CYFRA-21.1) discriminated between malignancy-related ascites and non-malignant ascites with an accuracy of 98.8% compared with an accuracy of 77.8% for cytological examination. In conclusion, the use of a discriminant function constructed from a combination of CA15-3, CEA and CYFRA-21.1 could distinguish malignant from non-malignant ascites with greater accuracy than cytological examination. Further studies in larger population groups are warranted.Öğe Inhibitors in hemophilia A and B in Souteast of Turkey(Ferrata Storti Foundation, 2007) Pasa, S.; Altintas, A.; Cil, T.; Atayan, Y.; Ayyildiz, O.[Abstract Not Available]Öğe NT-Probnp levels to perspectively assess acut cardiac failure after adjuvant doxorubicine therapy in early breast cancer patients(Amer Soc Clinical Oncology, 2008) Cil, T.; Altintas, A.; Pasa, S.; Kaplan, M. A.; Alan, S.; Isikdogan, A.[Abstract Not Available]Öğe Parathyroid hormone as a marker for the differential diagnosis of acute and chronic renal failure(Taylor & Francis Ltd, 2007) Ozmen, S.; Danis, R.; Akin, D.; Cil, T.; Yazanel, O.It is often difficult to distinguish acute renal failure clinically from chronic renal failure, especially in patients who do not have records of their medical history. We investigated the magnitude of iPTH increase in ARF and the potential role of i1PTH as a marker for differential diagnosis of ARF and CRF in new patients referred to our renal unit. We prospectively analyzed 122 (ARF n = 64, CRF n = 58) patients referred to our renal unit with serum creatinine higher than 2 mg/dL. ROC curve analysis was performed to investigate role of iPTH for differentiating ARF from CRF. The sensitivity, specificity, and positive predictive value of iPTH in discrimination of ARF and CRF were calculated. There was no statistically significant difference regarding the means of age, sex distribution, and serum chemistry between patients with ARF or CRF. But serum iPTH (D < 0.0001) levels were lower in patients with ARF than in those with CRF. A cutoff, set at 170pg/mL for iPTH to discriminate patients with CRF, yielded a sensitivity of 88% and a specificity of 89%. This study confirms that the iPTH measurement is of clinical value in differentiating acute from chronic renal failure.Öğe PREVALENCE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES POSITIVITY IN PATIENTS WITH HODGKIN AND NON-HODGKIN LYMPHOMA(Oxford Univ Press, 2008) Cil, T.; Altintas, A.; Pasa, S.; Isikdogan, A.[Abstract Not Available]Öğe Pulmonary hypertension in essential thrombocythemia(Ferrata Storti Foundation, 2007) Altintas, A.; Boyraz, T.; Pasa, S.; Cil, T.; Kaplan, M. A.; Ayyildiz, O.[Abstract Not Available]Öğe Reduced folat carrier gene status in colorectal, gastric, and pancreatic cancer(Amer Soc Clinical Oncology, 2009) Cil, T.; Tuzun, A. Y.; Altintas, A.; Batum, S.; Isikdogan, A.; Yurt, M.[Abstract Not Available]Öğe A simple way to estimate mean plasma glucose and to identify Type 2 diabetic subjects with poor glycaemic control when a standardized HbA1c assay is not available(Wiley, 2006) Ozmen, S.; Cil, T.; Atay, A. E.; Tuzcu, A. K.; Bahceci, M.Aims To evaluate the relationship between HbA(1c) and fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels, and to estimate the mean plasma glucose (mPG) derived from FPG and PPG that would predict Type 2 diabetic subjects with poor glycaemic control. Methods FPG, PPG and HbA(1c) values from 565 Type 2 diabetic patients (247 men and 318 women) were recorded. Linear regression analysis and Pearson's correlation was used to determine the relationship between HbA(1c), FPG and PPG. FPG and PPG were included as explanatory variables of HbA(1c) in linear regression analysis. Results The American Diabetes Association's objective of achieving an HbA(1c) level < 7.0% was obtained in 26.2% of the patients. The coefficients of FPG and PPG which determined HbA(1c) were similar. Therefore, mPG was calculated using the equation (FPG + PPG)/2. Pearson's correlation coefficient for HbA(1c) and FPG, PPG and mPG were 0.723 (P < 0.0001), 0.734 and 0.761 (P < 0.0001), respectively. A mPG cut-off value of 10 mmol/l predicted an HbA(1c) > 7% in the whole population, with a sensitivity of 84.2% and specificity of 80.4%. The area was high (0.90) in receiver-operating characteristic (ROC) curve analysis performed to examine the performance of mPG to predict HbA(1c) > 7%. Conclusions The mPG derived from FPG and PPG correlates strongly with HbA(1c). We therefore suggest that using a cut-off of 10 mmol/l for mPG may be appropriate in diabetes management in the primary-care setting, where most management of Type 2 diabetes occurs.Öğe Successful total hip replacement in a patient with severe haemophilia A with inhibitors using recombinant factor VIIa(Blackwell Publishing, 2008) Pasa, S.; Altintas, A.; Cil, T.; Danis, R.; Subasi, M.; Ayyildiz, O.; Muftuoglu, E.[Abstract Not Available]Öğe Vascular endothelial growth factor (VEGF) level in differential diagnosis of malignant and benign effusion(Amer Soc Clinical Oncology, 2010) Kaplan, M. A.; Isikdogan, A.; Zincircioglu, S. B.; Poyraz, T.; Cil, T.; Kucukoner, M.; Inal, A.[Abstract Not Available]
